Pharmaceuticals
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings
ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2022-11-28 08:00
5856
Venus Medtech to showcase its structural heart treatments at London Valves 2022
The company's growing number of solutions for structural heart disease will be presented at multiple events during the conference betweenNovember 27-29 HANGZHOU, China, Nov. 25, 2022 /PRNewswire/ -- Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The co...
2022-11-25 18:08
8227
Australian Scientists Honoured with the Grand Hamdan Award
DUBAI, UAE, Nov. 25, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future. The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of SheikhRas...
2022-11-25 10:39
4180
AstraZeneca Thailand Wins Two ACES Awards 2022: "Industry Champions of the Year" and "Community Initiative"
BANGKOK, Nov. 25, 2022 /PRNewswire/ -- AstraZeneca (Thailand) Co., Ltd., was
recently honoured with two accolades in the categories ofIndustry Champions of
the Year and Community Initiative at the Asia Corporate Excellence &
Sustainability Awards 2022(ACES Awards 2022).
2022-11-25 10:00
5168
AcuCort signs its first commercial agreement for the company's drug Zeqmelit™
LUND, Sweden, Nov. 24, 2022 /PRNewswire/ -- AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global biopharmaceutical company Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA). The agreement gives Kamada the exclusive...
2022-11-24 00:42
4152
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...
2022-11-23 19:43
5078
3Z: Zebrafish mutant model reveals novel drug candidates for ADHD
REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the ...
2022-11-22 10:54
3279
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology
SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at t...
2022-11-22 09:18
4864
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with rec...
2022-11-22 04:59
3947
Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreeme...
2022-11-21 19:00
3715
OLON, INTERNATIONAL API SUPPLIER, RELEASES THE NEW SUSTAINABILITY REPORT 2022 CONFIRMING THE PROGRESS OF ITS SUSTAINABILITY IN THE FOCUS AREAS OF ENVIRONMENT, SUPPLY CHAIN, PEOPLE, COMMUNITY ENGAGEMENT, PRODUCTION
"Our ambition is to promote a more sustainable production of APIs, meeting the highest standards of quality"Paolo Tubertini, CEO of the Group, commented "To achieve this, we are investing in people, in innovation and technology processes, endorsing the sustainable development goals proposed by th...
2022-11-21 18:00
3112
Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased to announce that in order to meet the rapidly growing market demand for HPV 9-valent vaccines inChina and ...
2022-11-21 16:07
3904
BGI Group Signs MOUs in Indonesia to Support Genomics Development
SHENZHEN, China, Nov. 21, 2022 /PRNewswire/ -- BGI Group signed three Memorandum of Understandings (MOUs) in the lead up to the G20 Summit inBali with the Indonesian Ministry of Health, the University ofIndonesia and the Del Institute of Technology (Institut Teknologi Del). The MOUs cover geno...
2022-11-21 14:33
3629
Abbott Launches Panbio(TM) HIV Self Test at Retail, Increasing Access to Faster, Reliable and Discrete Testing at Home
* Over-the-counter HIV self-tests can help overcome barriers, including healthcare access and stigma associated with HIV testing, while helping to expand screening * Fast, private and easy-to-use at home, Panbio™ HIV Self Test is a fingerstick blood test that detects HIV-1 and HIV-2 antibodie...
2022-11-21 13:49
7981
MEDICAL CITY CEO NAMED MOST INSPIRING EXECUTIVE AT ACES AWARDS 2022
MANILA, Philippines, Nov. 21, 2022 /PRNewswire/ -- Dr. Eugene F. Ramos, Chief Executive Officer of The Medical City (TMC), was named one ofAsia's most inspiring executives at the Asia Corporate Excellence & Sustainability Awards (ACES) 2022. The award, created to identify successful visionaries a...
2022-11-21 09:00
3553
ACROBiosystems Launches a New Logistics Center in Switzerland to Help Accelerate Drug Development throughout Europe
BASEL, Switzerland, Nov. 18, 2022 /PRNewswire/ -- ACROBiosystems Group has announced the launch of its first European logistics center and warehouse in Basel, Switzerland. This marks the first step towards ACROBiosystems' commitment to globalization by providing swift deliveries to their pharmace...
2022-11-18 20:41
2705
Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation
A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the ...
2022-11-17 10:00
4613
Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA
--While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval inChina will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor HANGZHOU and SHAOXING, China, Nov. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ...
2022-11-17 08:10
5079
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021
VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...
2022-11-16 21:00
5822
MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System
MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VA...
2022-11-16 19:55
3586
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9345
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8644
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8443
